Spark Therapeutics, Inc. (ONCE) financial statements (2021 and earlier)

Company profile

Business Address 3737 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments454520296294
Cash and cash equivalents959759294
Short-term investments358423237 
Receivables4781717
Inventory, net of allowances, customer advances and progress billings26   
Inventory26   
Prepaid expense41   
Other undisclosed current assets 521
Total current assets:567533315312
Noncurrent Assets
Property, plant and equipment96622017
Long-term investments and receivables952022 
Long-term investments952022 
Intangible assets, net (including goodwill)111 
Goodwill111 
Restricted cash and investments53   
Other noncurrent assets2111
Other undisclosed noncurrent assets  15 
Total noncurrent assets:247845918
TOTAL ASSETS:814617374330
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54392410
Accounts payable19141010
Accrued liabilities352514 
Debt500 
Deferred rent credit1
Deferred revenue and credits1366
Other liabilities22  
Other undisclosed current liabilities   7
Total current liabilities:62543022
Noncurrent Liabilities
Long-term debt and lease obligation4611 
Long-term debt, excluding current maturities4611 
Liabilities, other than long-term debt209491117
Deferred revenue and credits81117
Contract with customer, liability160
Deferred rent credit11
Other liabilities3940  
Other undisclosed noncurrent liabilities  1 
Total noncurrent liabilities:255491417
Total liabilities:3181034439
Stockholders' equity
Stockholders' equity attributable to parent497514330291
Common stock0000
Treasury stock, value(5)(1)(1)(1)
Additional paid in capital1,0921,027584420
Accumulated other comprehensive loss(1)(6)(1) 
Accumulated deficit(590)(506)(252)(129)
Total stockholders' equity:497514330291
TOTAL LIABILITIES AND EQUITY:814617374330

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net122022
Gross profit:65122022
Operating expenses(258)(271)(146)(69)
Operating loss:(194)(259)(125)(47)
Nonoperating income110  0
Investment income, nonoperating   0
Other nonoperating income110   
Loss from continuing operations before income taxes:(84)(259)(125)(47)
Income tax expense (benefit)(0)1  
Net loss:(84)(258)(125)(47)
Other undisclosed net income attributable to parent542 
Net loss attributable to parent:(79)(253)(124)(47)
Preferred stock dividends and other adjustments   (1)
Net loss available to common stockholders, diluted:(79)(253)(124)(48)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(84)(258)(125)(47)
Other comprehensive loss (5)  
Comprehensive loss:(84)(263)(125)(47)
Other undisclosed comprehensive income, net of tax, attributable to parent541 
Comprehensive loss, net of tax, attributable to parent:(79)(259)(124)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: